

*Nobel-prize caliber technology, a powerful and flexible  
intra/trans dermal delivery platform, a game-changing  
infection-control product, and a world-class management team*

Microdermis Corporation is a nimble life sciences company with an innovative Amidermal® dermatological delivery platform. Microdermis' business focuses on development of novel over-the-counter products that combine known, proven active ingredients with its unique Amidermal® delivery system to produce compelling products with significantly-enhanced performance, low manufacturing costs, and rapid time-to-market. Microdermis' flagship product, Provodine®, is a groundbreaking infection-control product that clearly demonstrates the power and flexibility of the Amidermal® platform. Microdermis has a full pipeline of further products in active development that will follow closely behind the commercial roll-out of Provodine®. Microdermis actively targets both military and civilian applications of its technologies, both in the US and abroad, as it builds its commercial infrastructure and sales network.

### The Amidermal® Platform

Microdermis' foundation Amidermal® technology is based on over a decade of research and development inspired by Nobel Laureate Dr. Joshua Lederberg, a renowned US molecular biologist. The Amidermal® technology enables precise targeted delivery of active agents *to, into, and through* the layers of the skin. The fundamental chemistry of the Amidermal® system is extremely skin-friendly with ingredients that moisturize and nourish the skin, enhancing user comfort and compliance. The precise control of the depth of penetration, remarkable persistence, and very skin-friendly properties are the hallmark of products built upon this market-changing Amidermal® platform. These properties can provide significantly enhanced performance using well-known, proven active ingredients (as seen by the remarkable performance of Provodine® compared to other PVP-I-based products) as well as with new emerging APIs. This combination of drug and delivery system can enable groundbreaking new products with streamlined regulatory pathways at compelling manufacturing costs. The inherent flexibility of the Amidermal® platform allows widespread applicability to a number of product areas, including both the professional healthcare and personal care markets. To date, several pharmaceutical and personal care companies have entered into licensing arrangements with Microdermis, in areas ranging from fine fragrances to incontinence care and several positions in between.

### Provodine®

Provodine®—Microdermis' initial commercial product—is a next-generation professional antiseptic that meets or exceeds FDA requirements for use as a Surgical Scrub, Pre-Operative Skin Preparation, Healthcare Personnel Hand Wash, and First Aid Antiseptic. Microdermis' unique Amidermal® technology enables significantly enhanced kill strength, killing the most dangerous microbes. There are currently no known resistant strains to Provodine®, making it especially useful for deployment in challenging environments with an unknown mix of infection sources, such as in military field hospitals and with globally-deployed NGO personnel. The Amidermal® technology also extends the potency window of the active ingredient, with *persistence exceeding 6 hours*. All of this remarkable antimicrobial performance comes in a surprisingly skin-friendly lotion. Provodine® contains a proprietary blend of *ingredients that nourish and rebuild the skin*, eliminating dryness and cracking, which are not only uncomfortable, but also create portals for microbes. Healthy skin leads to better compliance with hand hygiene protocols. The remarkable performance of Provodine® has been demonstrated in a comprehensive series of tests and trials, both laboratory-based and in real-world clinical settings. Provodine® is undergoing continuous testing to establish further evidence of its market-disruptive capabilities.

### Microdermis Management

Leading the Microdermis team is its CEO, Mac Sweeney, who is a former U.S. Congressman and 30+ year business turnaround expert and private equity professional. He was a pioneer when he was elected to the U.S. Congress and appointed to the White House staff while still in his 20s. Following his political career, Mac Sweeney went on to early work as a Wall Street lawyer before captaining eight business turnarounds and startups and heading multiple business restructurings. He has led equity capital raises and large infrastructure project funding. He has built a world-class management team at Microdermis, consisting of experienced scientists, medical professionals, and experienced global leaders. The team is well-positioned for its aggressive commercial launch of Provodine® and future products, especially in the U.S. and Latin America.

### KEY INFORMATION

<b>Website</b>	www.microdermis.com
<b>Ownership</b>	Privately held
<b>Sector(s)</b>	Professional healthcare, infection control, drug delivery, personal care
<b>Platform</b>	Amidermal® delivery
<b>Products</b>	Provodine® (professional antiseptic) Provasure®** (radiation dermatitis) Provocept®** (incontinence-associated dermatitis)

\* coming soon



### Microdermis Corporation

103 Carnegie Center, Suite 300  
Princeton, NJ 08540

609.803.3456 phone  
609.803.3465 fax

info@microdermis.com